We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

8 hedge funds and large institutions have $898K invested in Oruka Therapeutics in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more capital invested

Capital invested by funds: $562K → $898K (+$336K)

0.47% less ownership

Funds ownership: 1.06% → 0.58% (-0.47%)

33% less funds holding

Funds holding: 12 → 8 (-4)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
8
Holders Change
-4
Holders Change %
-33.33%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$65

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$278K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$40.9K
3
TCM
Tekla Capital Management
Massachusetts
-$19.7K
4
Deutsche Bank
Deutsche Bank
Germany
-$8K
5
Victory Capital Management
Victory Capital Management
Texas
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$545K -$278K -4,251 -38%
TCM
2
Tekla Capital Management
Massachusetts
$215K -$19.7K -301 -10%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$138K -$40.9K -627 -26%
Deutsche Bank
4
Deutsche Bank
Germany
– -$8K -233 Closed
Victory Capital Management
5
Victory Capital Management
Texas
– -$2K -43 Closed
Bank of America
6
Bank of America
North Carolina
– +$65 +1 +33%

ORKA Hedge Fund Activity: Q2 2020 in Review

8 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2020, worth a combined $898K — up 60% from $562K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ORKA and 0 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Bank of America, adding an estimated $65. The largest seller was Renaissance Technologies, cutting an estimated $278K.

  • 8 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2020, down from 12 in Q1 2020.
  • Funds reported $898K of Oruka Therapeutics stock for Q2 2020, up 60% quarter-over-quarter.
  • 0 funds opened new Oruka Therapeutics positions in Q2 2020 and 4 closed out, a net change of -4 holders.
  • The largest Oruka Therapeutics buyer in Q2 2020 was Bank of America, an estimated $65 added.
  • The largest Oruka Therapeutics seller in Q2 2020 was Renaissance Technologies, an estimated $278K sold.

Based on aggregated 13F filings for Q2 2020.